Alpine Immune Sciences Inc (NASDAQ:ALPN) Given Average Rating of “Buy” by Brokerages

Alpine Immune Sciences Inc (NASDAQ:ALPN) has earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $9.79.

Several brokerages recently weighed in on ALPN. Zacks Investment Research raised Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a report on Thursday, May 21st. Oppenheimer restated a “buy” rating and issued a $12.00 price target on shares of Alpine Immune Sciences in a research report on Thursday, May 14th. Piper Sandler reiterated an “overweight” rating and set a $8.00 price objective on shares of Alpine Immune Sciences in a research report on Tuesday, May 26th. Wedbush reiterated an “outperform” rating and set a $10.00 price objective on shares of Alpine Immune Sciences in a research report on Tuesday, May 26th. Finally, ValuEngine upgraded Alpine Immune Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd.

Shares of ALPN stock traded up $0.18 during trading hours on Tuesday, hitting $3.88. The stock had a trading volume of 33,300 shares, compared to its average volume of 18,491. The firm has a market capitalization of $74.36 million, a PE ratio of -2.06 and a beta of 1.31. Alpine Immune Sciences has a twelve month low of $2.05 and a twelve month high of $5.35. The stock’s 50 day moving average is $3.20 and its 200 day moving average is $3.16. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.46 and a quick ratio of 7.46.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.17. Alpine Immune Sciences had a negative return on equity of 104.04% and a negative net margin of 1,236.45%. The business had revenue of $1.09 million during the quarter, compared to the consensus estimate of $0.38 million. As a group, equities analysts predict that Alpine Immune Sciences will post -1.38 earnings per share for the current year.

A hedge fund recently raised its stake in Alpine Immune Sciences stock. Renaissance Technologies LLC grew its position in Alpine Immune Sciences Inc (NASDAQ:ALPN) by 13.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,810 shares of the biotechnology company’s stock after purchasing an additional 15,449 shares during the period. Renaissance Technologies LLC owned approximately 0.69% of Alpine Immune Sciences worth $491,000 as of its most recent SEC filing. 43.87% of the stock is currently owned by hedge funds and other institutional investors.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

Featured Story: What is the Coverage Ratio?

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.